Skip to main content
. Author manuscript; available in PMC: 2013 Apr 1.
Published in final edited form as: Surg Oncol Clin N Am. 2012 Apr;21(2):301–316. doi: 10.1016/j.soc.2011.12.004

Figure 2. Recurrence-free survival in patients treated for 1 year with adjuvant imatinib or placebo following resection of localized, primary GIST (≥3cm).

Figure 2

From DeMatteo RP, Ballman KV et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 2009; 373(9669): 1097–1104; with permission.